Urothelial Bladder CarcinomaRSS

Last Updated: September 10, 2015

Sample Collection Complete Data Publicly Available
Selected Selected

What is urothelial bladder cancer?

Urothelial bladder cancer is the most common type of bladder cancer.  The bladder is a hollow organ that holds liquid waste, or urine, produced by the kidneys. Invasive bladder cancer develops in the inner lining of the bladder wall and grows finger-like projections, called papillary tumors, into the hollow part of the bladder.  In 2010, it was estimated that 70,500 people would be diagnosed with bladder cancer and an estimated 15,000 would die from it.1 Urothelial bladder cancer is more common among men than women.   From 2003-2007, the median age of death from bladder cancer was 78 years of age.  If the cancer is diagnosed after it has metastasized, as few as five percent of patients will be living five years after diagnosis.  View additional information on urothelial bladder cancer.

What have The Cancer Genome Atlas (TCGA) researchers learned about urothelial bladder cancer?

TCGA researchers have:

  • Identified known and novel molecular alterations in urotheilial bladder carcinoma, locating potential therapeutic targets in 69 percent of the tumors studied
      • The receptor tyrosine kinase (RTK)/RAS pathway involved in cell cycle signaling was altered in 44 percent of tumors
      • TP53, a tumor suppressor in the p53 signaling pathway was mutated in 49 percent of tumors and functionality inactive in 76 percent of cases
      • Her2, a mutation characteristic of some breast cancers, was frequently mutated, suggesting that a subset of urothelial bladder carcinomas may respond to Her2-specific breast cancer treatments
      • Genes involved in regulating chromatin, the structure of DNA and proteins that makes up chromosomes, were frequently mutated and represent novel targets for bladder cancer
  • Corroborated the previously observed association between smoking and bladder cancer, as 72 percent of tumors were from patients with a history of tobacco smoking
      • The genomic profiles of smokers were not distinct from those of nonsmokers

See more about TCGA's study on urothelial bladder carcinoma

Where can I find more information about the TCGA Research Network’s studies or studies using TCGA data?

View a list of TCGA scientific publications

Where can I find clinical trials to treat urothelial bladder carcinoma that are supported by the National Cancer Institute (NCI)?

View a list of NCI-supported urothelial bladder carcinoma clinical trials that are now accepting patients

Selected References

1American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society, 2010.